Cachexia therapy

恶病质治疗

• 批准号: nhmrc : 1075504
• 负责人: Dr Mark Hulett
• 金额: $ 50.95万
• 依托单位: La Trobe University
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/cachexia-therapy/455676
• 关键词: Cachexia; therapy

Cachexia is a major side effect of cancer, resulting in significant muscle wasting, fat loss and organ failure. Up to 80% of cancer patients suffer and 25% succumb to this condition. This significantly affects the treatment regimens of cancer patients and affects their quality of life. We have developed monoclonal antibodies that block and reverse cachexia in preclinical mouse cancer models. Our aims are to humanise the antibody and manufacture it for the first clinical trial in humans.

恶病质是癌症的主要副作用，导致显著的肌肉萎缩、脂肪减少和器官衰竭。高达80%的癌症患者患有这种疾病，25%的患者死于这种疾病。这显着影响癌症患者的治疗方案并影响他们的生活质量。我们已经开发了单克隆抗体，在临床前小鼠癌症模型中阻断和逆转恶病质。我们的目标是使抗体人源化，并将其用于人类的首次临床试验。